Development of Target-Based Antineoplastic Agents

[1]  J. Verweij,et al.  Matrix metalloproteinase inhibitors: Present achievements and future prospects , 1997, Investigational new drugs.

[2]  J. Biggs,et al.  Inhibitors of cyclin-dependent kinase and cancer , 1995, Journal of Molecular Medicine.

[3]  E. Eisenhauer,et al.  Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Ratain,et al.  Oral chemotherapy: rationale and future directions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Daniel,et al.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .

[6]  J. Nemunaitis,et al.  Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  D. V. Von Hoff.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998, Clinical Cancer Research.

[8]  W. A. Galloway,et al.  Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. , 1998, British journal of clinical pharmacology.

[9]  L. Benet,et al.  Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.

[10]  A. Harris.  Antiangiogenesis for cancer therapy , 1997, The Lancet.

[11]  M. Ratain,et al.  New phase I trial methodology. , 1997, Seminars in Oncology.

[12]  D. Back,et al.  Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV‐infected patients , 1997, AIDS.

[13]  A. Breckenridge,et al.  Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV‐infected patients , 1997, AIDS.

[14]  J. Urano,et al.  Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase , 1997, Journal of cellular biochemistry. Supplement.

[15]  G. Pasero,et al.  Is the control of disease progression within our grasp? Review of the GRISAR study. (Gruppo Reumatologi Italiani Studio Artrite Reumatoide). , 1996, British journal of rheumatology.

[16]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Kohn,et al.  Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. , 1996, Cancer research.

[18]  E. M. Bujaidar,et al.  The chemoprevention of cancer , 1996 .

[19]  G. Sledge,et al.  Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. , 1995, Journal of the National Cancer Institute.

[20]  P. Macdonald,et al.  Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. , 1995, The New England journal of medicine.

[21]  J. Kirwan,et al.  The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. , 1995, The New England journal of medicine.

[22]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[23]  M J Ratain,et al.  Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. , 1993, Journal of the National Cancer Institute.

[24]  M. Abrahamowicz,et al.  Randomized discontinuation trials: utility and efficiency. , 1993, Journal of clinical epidemiology.

[25]  H. Capell,et al.  The 'natural' history of active rheumatoid arthritis over 3-6 months--an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo. , 1993, British journal of rheumatology.

[26]  K E Peace,et al.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R F Woolson,et al.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. , 1992, The New England journal of medicine.

[28]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[29]  L. Whitfield,et al.  Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. , 1990, Cancer research.

[30]  H. Paulus,et al.  Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. , 1990, Arthritis and rheumatism.